1 |
Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48(1): 1-22.
DOI
ScienceOn
|
2 |
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Chest Physicians Evidence-Based Clinical Thrombosis (9th ed.). American College of Practice Guidelines. Chest 2012; 141: e419S-e494S.
|
3 |
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis (9th ed.). American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e278S-325S.
DOI
ScienceOn
|
4 |
Eriksson BI, Quinlan DJ. Oral anticoagulants in development; focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66(11): 1411-29.
DOI
|
5 |
Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3(3): 514-21.
DOI
ScienceOn
|
6 |
Depasse F, Busson J, Mnich J, et al. Effect of BAY 59- 7939-a novel, oral direct factor Xa inhibitor-on clotbound factor Xa activity in vitro [Abstract]. J Thromb Haemost 2005; 3 Suppl 1: P1104.
DOI
ScienceOn
|
7 |
Bayer Schering Pharma. (rivaroxaban 10 mg tablets): EU summary of product characteristics. Available on the internet:http://www.xarelto.com/en/ information-onxarelto/ vte-prevention-in-orthopaedic-surgery. [Last accessed June 2, 2013].
|
8 |
Grégoire JP, Moisan J, Potvin L, et al. Effect of drug utilization reviews on the quality of in-hospital prescribing: a quasi-experimental study. BMC Health Services Research 2006; 6: 33.
DOI
|
9 |
Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa ingibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37(5): 1056-64.
DOI
ScienceOn
|
10 |
Kakkar AK, Brenner B, Dahl OE, et al. RECORD2 Investigators. Extended duration rivaroxaban versus shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372(9632): 31-9.
DOI
ScienceOn
|
11 |
Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358(26): 2765-75.
DOI
ScienceOn
|
12 |
Garcia DA, Baglin TP, Weitz JI, et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis (9th ed.). American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012; 141: e24S-e43S.
|
13 |
National Institute for Health and Care Excellence (NICE) Guideline. Final appraisal determination-Rivaroxaban for prevention of venous thromboembolism after total hip or knee replacement in adults.Issue date: February 2009 Available on the internet: http://www.nice.org.uk/nicemedia/pdf/ RivaroxabanFAD.pdf. [Last accessed July 12, 2013].
|
14 |
Phillips MS, Gayman JE, Todd MW, et al. ASHP guidelines on medication-use evaluation. Am J Health Syst Pharm 1996; 53: 1953-5.
|
15 |
Health Insurance Reviews & Assessment Service. Healthcare Benefits Management. Available on the internet: http:// www.hira.or.kr. [Last accessed June 14, 2013].
|
16 |
Bergqvist D, Benoni G, Björgell O, et al. Low-molecularweight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335(10): 696-700.
DOI
ScienceOn
|
17 |
Planes A, Vochelle N, Darmon JY, et al. Risk of deepvenous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348(9022): 224-8.
DOI
ScienceOn
|
18 |
Eikelboom JW, Quinlan DJ, Douketis JD. Extendedduration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358(9275): 9-15.
DOI
ScienceOn
|
19 |
Dahl OE. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004; 64 Suppl 1: 17-25.
DOI
|
20 |
Hull RD, Pineo GF, Stein PD, et al. Extended out-ofhospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135(10): 858-69.
DOI
ScienceOn
|
21 |
O'Donnell M, Linkins LA, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med 2003; 163(11): 1362-6.
DOI
ScienceOn
|
22 |
Sanofi Korea. Product information. Clexane . Updated on April 22 2011. Available on the internet: http:// products.sanofi.co.kr/KR_Clexane_inj.pdf. [Last accessed May 22, 2013].
|
23 |
Agnelli G, Taliani MR, Verso M. Building effective prophylaxis of deep vein thrombosis in the outpatient setting. Blood Coagul Fibrinolysis 1999; 10 Suppl 2:S29-35.
|
24 |
Xing KH, Morrison G, Lim W, et al. Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials. Thromb Res 2008; 123(1): 24-34.
DOI
ScienceOn
|
25 |
Fujita S, Hirota S, Oda T, et al. Deep venous thrombosis after total of knee arthroplasty in patients in Japan. Clin Orthop Relat Res 2000; (300): 168-74.
|
26 |
Won MH, Lee GW, Lee TJ, et al. Prevalence and risk factors of thromboembolism after joint arthroplasty without chemical thromboprophylaxis in an Asian population. J Arthroplasty 2011; 26(7): 1106-11.
DOI
ScienceOn
|
27 |
Kim YH, Suh JS. Low incidence of deep-vein thrombosis after cementless total hip replacement. J Bone Joint Surg Am 1988; 70(6): 878-82.
|
28 |
Yoo MC, Kang CS, Kim YH, et al. A prospective randomized study on the use nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. Int Orthop 1997; 21(6): 399-402.
|
29 |
Zindel S, Stock S, Müller D, et al. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res 2012; 12: 192-205.
DOI
|
30 |
Duran A, Sengupta N, Diamantopoulos A, et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. Pharmacoeconomics 2012; 30(2): 87-101.
DOI
|
31 |
McDonald H, Diamantopoulos A, Wells P, et al. Costeffectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. J Med Econ 2012; 15(5): 817-28.
DOI
ScienceOn
|
32 |
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
DOI
ScienceOn
|
33 |
Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163(7): 759-68.
DOI
ScienceOn
|